Cingulate Therapeutics

Executive Summary

Cingulate Therapeutics is a clinical-stage biopharmaceutical company pioneering Precision Timed Release (PTR) drug delivery technology for CNS disorders. Its lead candidate, CTx-101, is a once-daily, multi-release formulation of methylphenidate for ADHD, which has demonstrated positive Phase 2 data showing improved adherence and symptom control. The company is currently advancing CTx-101 into Phase 3 trials and is also developing a pipeline for anxiety disorders. With a proprietary platform that enables customizable drug release profiles, Cingulate aims to address significant unmet needs in medication adherence and therapeutic outcomes. The company remains private but has received substantial investor interest, with a valuation around $71 million. Key near-term milestones include Phase 3 data readouts and potential regulatory interactions that could de-risk the platform and lead to commercial partnerships.

Upcoming Catalysts (preview)

• Q2 2027Phase 3 top-line data for CTx-101 in ADHD45% success
• Q4 2026Initiation of Phase 2b trial for anxiety candidate70% success
• Q1 2027Strategic partnership or licensing deal for PTR platform55% success